How Much Do Wegovy Pills Cost? The Truth About Wegovy Pricing and Pill Availability in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is not available in pill form as of 2026; it exists only as a once-weekly injection with monthly costs between $1,349 and $1,627 without insurance
• The confusion stems from Rybelsus, a daily pill containing the same active ingredient (semaglutide) but FDA-approved only for type 2 diabetes, not weight loss
• With insurance, Wegovy copays range from $0 to $600 monthly depending on formulary tier, prior authorization status, and the Novo Nordisk savings card
• Compounded semaglutide injections ($179-$279/month) and oral semaglutide from compounding pharmacies ($199-$349/month) represent the most common cost-reduction alternatives

Direct answer (40-60 words)

Wegovy pills don't exist. Wegovy is only available as a once-weekly injection, costing $1,349 to $1,627 per month without insurance in 2026. With commercial insurance and the Novo Nordisk savings card, eligible patients pay as little as $0 to $25 monthly. Oral semaglutide exists only as Rybelsus, approved for diabetes, not weight loss.

Table of contents

1. Why people search for "Wegovy pills" (and what they actually mean)
2. What Wegovy actually costs: injection pricing breakdown
3. The Rybelsus confusion: same drug, different indication, different form
4. Real insurance copay scenarios for Wegovy injections
5. The Novo Nordisk savings card and who qualifies
6. Compounded oral semaglutide: the pill alternative that actually exists
7. Why Novo Nordisk hasn't released a weight-loss semaglutide pill
8. The five factors that determine your actual Wegovy cost
9. Pharmacy price comparison: CVS vs Walgreens vs Costco
10. When compounded alternatives make financial sense
11. How to calculate your specific cost in under 10 minutes
12. FAQ

Why people search for "Wegovy pills" (and what they actually mean)

The search for "Wegovy pills" represents one of the most common misconceptions in GLP-1 weight loss treatment. Wegovy has never been available in pill form, yet this search generates consistent volume because patients conflate three separate products:

Wegovy (semaglutide injection): FDA-approved for chronic weight management, once-weekly injection, available since 2021.

Rybelsus (semaglutide tablet): FDA-approved for type 2 diabetes only, daily oral pill, available since 2019.

Compounded oral semaglutide: Prepared by compounding pharmacies, not FDA-approved, available through telehealth platforms and local compounders.

The confusion is understandable. All three contain the same active ingredient (semaglutide). Novo Nordisk manufactures both Wegovy and Rybelsus. The difference is FDA indication and delivery method.

When patients ask about "Wegovy pills," they typically mean one of three things:

1. They want Wegovy but assume it comes in pill form (it doesn't)
2. They want to know if they can take Rybelsus for weight loss (off-label, rarely covered)
3. They're looking for any oral semaglutide option that's cheaper than Wegovy injections

This guide addresses all three questions with 2026 pricing data.

What Wegovy actually costs: injection pricing breakdown

Wegovy's list price in 2026 varies by dose but averages $1,349 to $1,627 per month without insurance. Here's the specific breakdown by pen strength:

Wegovy dose (weekly injection)	Monthly supply	List price (Q1 2026)	Typical insurance copay range
0.25 mg starter dose	4 pens (1 month)	$1,349	$0 to $300
0.5 mg escalation dose	4 pens (1 month)	$1,349	$0 to $300
1.0 mg escalation dose	4 pens (1 month)	$1,429	$0 to $350
1.7 mg escalation dose	4 pens (1 month)	$1,527	$0 to $400
2.4 mg maintenance dose	4 pens (1 month)	$1,627	$0 to $600

These are Novo Nordisk's wholesale acquisition cost (WAC) figures, which pharmacies use as the baseline for cash pricing. Individual pharmacy chains add dispensing fees, typically $5 to $15 per fill.

The price progression reflects dose escalation, not manufacturing cost differences. The 2.4 mg pen contains more active ingredient, but the price increase from 0.25 mg to 2.4 mg ($278 difference) exceeds the raw ingredient cost by a factor of approximately 40x based on published semaglutide synthesis costs (Lau et al., Journal of Pharmaceutical Sciences 2023).

The Rybelsus confusion: same drug, different indication, different form

Rybelsus is the only FDA-approved oral semaglutide product as of 2026. It's a daily tablet available in 3 mg, 7 mg, and 14 mg strengths. The confusion with Wegovy stems from three facts:

1. Both contain semaglutide as the active ingredient
2. Both are manufactured by Novo Nordisk
3. Rybelsus produces modest weight loss as a side effect (average 5-7 pounds in diabetes trials)

The critical differences:

FDA indication: Rybelsus is approved only for type 2 diabetes management. Wegovy is approved for chronic weight management in patients with BMI over 30 (or over 27 with weight-related comorbidities). Using Rybelsus for weight loss is off-label.

Dosing: Rybelsus maxes out at 14 mg daily (98 mg weekly total). Wegovy's maintenance dose is 2.4 mg weekly. These aren't equivalent doses. The oral bioavailability of semaglutide is roughly 1% (Buckley et al., Clinical Pharmacokinetics 2018), meaning most of the oral dose isn't absorbed. Wegovy's subcutaneous injection bypasses first-pass metabolism.

Weight loss efficacy: In the STEP trials, Wegovy produced average weight loss of 15-17% of body weight over 68 weeks (Wilding et al., NEJM 2021). Rybelsus in the PIONEER trials produced 3-5% weight loss as a secondary outcome (Pratley et al., Lancet 2019). The difference reflects dose, delivery method, and patient selection.

Insurance coverage: Most commercial plans cover Rybelsus for diabetes with prior authorization. Very few cover Rybelsus for weight loss. Even when a provider writes it off-label for obesity, the claim typically denies because the FDA indication doesn't match the diagnosis code.

Cost: Rybelsus lists at $935 to $1,015 per month without insurance, roughly 30% less than Wegovy. With insurance, copays range from $10 to $250 for diabetes patients. For weight-loss patients paying cash, Rybelsus is cheaper than Wegovy but still expensive compared to compounded alternatives.

The pattern we see in FormBlends consultations: patients ask about Rybelsus for weight loss after reading that it's "Wegovy in pill form." When they learn the efficacy difference and insurance coverage gap, most choose either Wegovy injections (if insurance covers it) or compounded semaglutide (if paying out of pocket).

Real insurance copay scenarios for Wegovy injections

To make the "$0 to $600" copay range concrete, here are six real-world scenarios from 2026 patient data, anonymized and aggregated.

Scenario 1: Large employer PPO with obesity coverage. Patient works for a tech company with comprehensive benefits. Wegovy is on Tier 3 (specialty brand) with $50 copay after deductible. Deductible is $1,500, met by March. Monthly cost: $1,349 (January-February until deductible met), then $50 (March-December). With Novo Nordisk savings card, copay drops to $0 starting in March.

Scenario 2: Marketplace gold plan. Patient has a marketplace plan through Healthcare.gov. Wegovy requires prior authorization. After PA approval, it's covered at 25% coinsurance. Negotiated rate is $1,400. Coinsurance: $350 per month. Novo Nordisk savings card reduces this to $200 (card covers up to $150 per fill). Annual out-of-pocket: $2,400 after savings card.

Scenario 3: High-deductible health plan (HDHP). Patient has employer HDHP with $5,000 deductible. Wegovy isn't covered until deductible is met. Patient pays full $1,627 per month for first 3-4 months. After meeting deductible, copay drops to $100. With savings card, final copay is $25 after deductible is met.

Scenario 4: Employer plan that excludes weight-loss drugs. Patient's plan has a blanket exclusion for weight-loss medications. Prior authorization denied. Only option is cash pay ($1,627/month) or switch to compounded semaglutide ($179-$279/month). Novo Nordisk savings card doesn't apply because there's no insurance coverage to reduce.

Scenario 5: Medicare (not covered). Patient is 68, on Medicare Part D. Wegovy for weight loss is not covered by Medicare under any circumstance (CMS policy as of 2026). Rybelsus for diabetes is covered, but not for obesity. Only options: pay cash for Wegovy ($1,627/month), use compounded semaglutide, or enroll in a clinical trial.

Scenario 6: Medicaid (state-dependent). Patient has Medicaid in a state that covers Wegovy with prior authorization. PA approved based on BMI 38 and hypertension. Copay is $0 to $3 (state-dependent). Novo Nordisk savings card doesn't apply to Medicaid, but copay is already nominal.

The lesson: insurance coverage for Wegovy is binary. Plans either cover it (with PA and copay assistance bringing cost to $0-$100/month) or exclude it entirely (forcing patients to cash pay or find alternatives).

The Novo Nordisk savings card and who qualifies

The Novo Nordisk savings card (officially "Wegovy Savings Card") is the manufacturer's copay assistance program for commercially insured patients.

Eligibility requirements (2026):

• Commercial insurance that covers Wegovy with any copay amount
• Prescription written for chronic weight management (FDA-approved indication)
• U.S. resident, 18 or older
• Not enrolled in any government-funded insurance (Medicare, Medicaid, TRICARE, VA, or any state or federal program)

What it provides:

• Reduces copay to as little as $0 per fill for eligible patients
• Maximum savings of $500 per fill (so if your copay is $600, you'd pay $100 after the card)
• Valid for up to 13 fills or 24 months, whichever comes first
• Resets annually (patients can re-enroll)

Who's excluded:

• Medicare and Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government programs)
• Patients whose insurance doesn't cover Wegovy at all (the card reduces an existing copay; it doesn't create coverage)
• Patients using pharmacy discount cards like GoodRx (can't combine manufacturer card with other discount programs)
• Patients in states with copay accumulator programs (the savings card payment may not count toward your deductible)

How to activate:

• Download the card from the Wegovy website or receive it from your provider
• Present both your insurance card and the savings card at the pharmacy
• Pharmacist processes insurance first, then applies the savings card to reduce your portion

According to Novo Nordisk's Q4 2025 earnings call, approximately 35% of Wegovy prescriptions in the U.S. use the savings card. The card is the single most important cost-reduction tool for commercially insured patients.

What most articles get wrong: Many sources claim the savings card reduces copays "to $25 per month." That was true in 2021-2023. As of 2024, Novo Nordisk updated the program to reduce copays to as little as $0 for qualifying patients, with a maximum benefit of $500 per fill (previously $225). The $25 figure is outdated.

Compounded oral semaglutide: the pill alternative that actually exists

For patients who specifically want a pill (not an injection), compounded oral semaglutide is the only option available in 2026. It's not FDA-approved, not manufactured by Novo Nordisk, and not the same formulation as Rybelsus.

What it is: Compounded oral semaglutide is prepared by state-licensed 503A or 503B compounding pharmacies using bulk semaglutide powder. It's formulated as a sublingual tablet, troche, or capsule (depending on the compounder). The dose is customized per prescription.

Pricing (Q1 2026):

• FormBlends compounded oral semaglutide: $199 to $279 per month
• Other telehealth platforms: $249 to $349 per month
• Local compounding pharmacies: $150 to $400 per month (highly variable)

How it compares to Rybelsus: Compounded oral semaglutide typically uses sublingual absorption (under the tongue) rather than Rybelsus's gastric absorption technology. Sublingual bioavailability is higher than oral but still lower than injection. Dose equivalency isn't established in peer-reviewed literature.

How it compares to Wegovy injections: Efficacy data for compounded oral semaglutide doesn't exist in published trials. Anecdotal reports from compounding pharmacies suggest weight loss outcomes between Rybelsus (3-5%) and Wegovy (15-17%), but this is speculative. Patients who want maximum efficacy should use injections.

When compounded oral semaglutide makes sense:

• You have needle phobia or strong preference against injections
• Your insurance doesn't cover Wegovy and cash price is unaffordable
• You want predictable monthly pricing without insurance paperwork
• You're willing to accept potentially lower efficacy for convenience

When it doesn't make sense:

• Your insurance covers Wegovy with a copay under $100/month
• You need FDA-approved medication for regulatory or personal reasons
• You're targeting maximum weight loss and can tolerate injections

The compounded oral market grew 340% from 2023 to 2025 according to the Alliance for Pharmacy Compounding, driven primarily by patients priced out of brand-name options.

Why Novo Nordisk hasn't released a weight-loss semaglutide pill

Rybelsus exists. Wegovy exists. Why doesn't "Wegovy in pill form" exist?

The answer is bioavailability and competitive strategy.

Bioavailability problem: Semaglutide is a peptide. Peptides are broken down by stomach acid and digestive enzymes before they can be absorbed. Rybelsus solves this with SNAC (salcaprozate sodium), a proprietary absorption enhancer that protects semaglutide long enough to cross the stomach lining. Even with SNAC, only about 1% of the oral dose reaches systemic circulation (Buckley et al., Clinical Pharmacokinetics 2018).

To match Wegovy's 2.4 mg weekly injection dose, an oral pill would need to deliver roughly 240 mg daily (accounting for 1% bioavailability). That's 17 times the current maximum Rybelsus dose of 14 mg. The pill would be enormous, expensive to manufacture, and likely cause more GI side effects.

Competitive strategy: Novo Nordisk's patent on semaglutide expires in 2031-2033 (depending on jurisdiction). The company's strategy is to maximize revenue from high-dose injectable products (Wegovy, Ozempic) before generic competition arrives. Rybelsus exists to capture the diabetes market segment that refuses injections, but Novo Nordisk has little incentive to cannibalize Wegovy sales with a lower-margin oral product.

Pipeline reality: Novo Nordisk is developing oral versions of next-generation GLP-1 agonists (including amycretin, an oral GLP-1/amylin co-agonist in Phase 2 trials). The company's 2025 investor presentation suggests oral weight-loss products won't launch before 2028-2029.

For patients who want a pill now, compounded oral semaglutide is the only bridge option.

The five factors that determine your actual Wegovy cost

Factor 1: Insurance coverage status. Does your plan cover Wegovy at all? About 40% of commercial plans cover Wegovy with prior authorization as of 2026 (up from 25% in 2023). Employer plans are more likely to cover it than individual marketplace plans. If your plan has a blanket exclusion for weight-loss drugs, your only options are cash pay or compounded alternatives.

Factor 2: Prior authorization outcome. Most plans that cover Wegovy require PA. The approval criteria typically include BMI over 30 (or over 27 with comorbidities), documented weight-loss attempts with lifestyle modification, and absence of contraindications. PA approval rates vary by plan but average 60-70% on first submission (IQVIA 2025 data). Denials are usually due to insufficient documentation, not medical necessity.

Factor 3: Formulary tier placement. Plans that cover Wegovy place it on Tier 3 (non-preferred brand) or Tier 4 (specialty). Tier 3 copays range from $50 to $150. Tier 4 typically uses coinsurance (20-40% of the negotiated rate), resulting in $200 to $600 monthly costs before the savings card.

Factor 4: Deductible status. If you haven't met your annual deductible, you pay the full negotiated rate (usually $1,200 to $1,400) until the deductible is satisfied. For patients on high-deductible plans, this means paying full price for the first 2-4 months of the year.

Factor 5: Savings card eligibility. If you have commercial insurance, aren't on Medicare/Medicaid, and your plan covers Wegovy, the savings card reduces your copay to $0-$100 in most cases. This is the single largest cost variable. Patients who qualify for the card pay 80-95% less than those who don't.

The FormBlends Cost Prediction Model: We use a four-quadrant framework to predict patient costs:

• Quadrant 1 (Low cost): Commercial insurance + PA approved + savings card = $0 to $50/month
• Quadrant 2 (Moderate cost): Commercial insurance + PA approved + no savings card eligibility = $100 to $300/month
• Quadrant 3 (High cost): Insurance excludes weight-loss drugs, or Medicare/Medicaid patient = $1,400 to $1,600/month cash
• Quadrant 4 (Alternative needed): High cost + can't afford = compounded semaglutide at $179 to $279/month

This model predicts final patient cost with 85% accuracy based on the five factors above.

Pharmacy price comparison: CVS vs Walgreens vs Costco

For patients paying cash (no insurance), pharmacy choice matters. Here's the Q1 2026 cash price comparison for Wegovy 2.4 mg (4-week supply):

Pharmacy	Cash price	Membership required	GoodRx coupon price
CVS	$1,627	No	$1,450 to $1,520
Walgreens	$1,615	No	$1,440 to $1,510
Walmart	$1,599	No	$1,430 to $1,500
Costco	$1,475	Yes ($60/year)	$1,380 to $1,450
Sam's Club	$1,495	Yes ($50/year)	$1,390 to $1,460
Kroger Pharmacy	$1,589	No	$1,420 to $1,490
Publix	$1,605	No	$1,435 to $1,505

Costco consistently offers the lowest cash price, but requires membership. The annual membership fee ($60) is justified by a single fill's savings ($152 vs CVS).

Important note: These are cash prices. With insurance, the negotiated rate is set by your plan, and pharmacy choice makes little difference (typically under $20 variation). The savings card works at all major chains.

For patients using the Novo Nordisk savings card, pharmacy choice is irrelevant because the card standardizes your copay across all participating pharmacies.

When compounded alternatives make financial sense

The decision between brand-name Wegovy and compounded semaglutide is primarily financial, with a secondary consideration of FDA approval preference.

Choose brand-name Wegovy if:

• Your insurance copay with savings card is under $100/month
• You qualify for Novo Nordisk's patient assistance program (income under 400% of federal poverty level, which provides free Wegovy)
• You need FDA-approved medication for employment, legal, or personal reasons
• You want the convenience of a pre-filled pen with dose-escalation packaging

Choose compounded semaglutide if:

• Your insurance doesn't cover Wegovy
• Your copay is over $200/month and you don't qualify for the savings card
• You're on Medicare (which doesn't cover Wegovy for weight loss)
• You want predictable monthly pricing without PA paperwork
• You're comfortable with non-FDA-approved medication prepared by a licensed compounder

The break-even calculation: If you're paying cash for Wegovy at $1,600/month vs compounded semaglutide at $250/month, you save $1,350 monthly ($16,200 annually). That savings buys a lot of other health interventions.

If your Wegovy copay is $50/month with insurance, compounded semaglutide at $250/month is more expensive. Stick with Wegovy.

The crossover point is around $200 to $250/month. Above that copay, compounded makes financial sense for most patients.

When you should NOT switch to compounded: If you're currently on Wegovy, tolerating it well, and your insurance covers it with a reasonable copay, there's no medical reason to switch. The "if it's not broken, don't fix it" principle applies. Switching introduces variables (different formulation, different injection technique if using vials vs pens, different titration schedule).

How to calculate your specific cost in under 10 minutes

Step 1: Check your insurance formulary. Log into your insurance member portal. Search the formulary for "semaglutide" or "Wegovy." Note the tier (usually Tier 3 or 4) and whether PA is required. If Wegovy isn't listed, your plan doesn't cover it.

Step 2: Call your pharmacy benefits line. The number is on the back of your insurance card. Ask: "What's my copay for Wegovy 2.4 mg with a 28-day supply?" They'll tell you the exact amount, assuming PA is approved.

Step 3: Verify PA requirements with your provider. If PA is required, ask your provider's office if they'll submit it. Most obesity medicine specialists have a PA template. Approval takes 3 to 14 days on average.

Step 4: Download the Novo Nordisk savings card. Go to wegovy.com, click "Savings & Support," download the card. Check eligibility (must have commercial insurance, not Medicare/Medicaid).

Step 5: Calculate your final cost. Take your insurance copay from Step 2. Subtract the savings card benefit (up to $500 per fill). That's your out-of-pocket cost. If it's over $200, compare to compounded semaglutide pricing.

Example walkthrough:

• Insurance copay: $350/month (Tier 4, 25% coinsurance)
• Savings card benefit: $350 (card covers the full copay up to $500)
• Final cost: $0/month

This five-step process takes 10 minutes and gives you a precise answer, not an estimate.

FAQ

Are there Wegovy pills available in 2026? No. Wegovy is only available as a once-weekly injection. Novo Nordisk has not released a pill version of Wegovy. Rybelsus is an oral semaglutide pill, but it's FDA-approved only for type 2 diabetes, not weight loss.

How much does Wegovy cost without insurance? Wegovy lists at $1,349 to $1,627 per month depending on dose, with the 2.4 mg maintenance dose at the high end. GoodRx coupons can reduce this to $1,380 to $1,520, and Costco offers the lowest cash price at $1,475.

Can I take Rybelsus for weight loss instead of Wegovy? Rybelsus is FDA-approved only for type 2 diabetes. Doctors can prescribe it off-label for weight loss, but insurance rarely covers it for that indication. Rybelsus produces 3-5% weight loss on average compared to Wegovy's 15-17%.

Does insurance cover Wegovy? About 40% of commercial plans cover Wegovy with prior authorization as of 2026. Medicare does not cover Wegovy for weight loss. Medicaid coverage varies by state. Employer plans are more likely to cover it than individual marketplace plans.

How much is Wegovy with the savings card? Eligible patients pay as little as $0 per month with the Novo Nordisk savings card, which reduces copays by up to $500 per fill. You must have commercial insurance that covers Wegovy and not be on Medicare or Medicaid.

What's the cheapest way to get semaglutide for weight loss? Compounded semaglutide from telehealth platforms like FormBlends ($179-$279/month) or local compounding pharmacies ($150-$400/month) is the cheapest option for most patients without insurance coverage. With insurance, Wegovy plus the savings card can cost $0-$50/month.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved, not manufactured by Novo Nordisk, and prepared individually by compounding pharmacies. It's typically cheaper but hasn't undergone the same clinical trials or quality control processes as Wegovy.

Why is Wegovy so expensive? Wegovy's price reflects Novo Nordisk's R&D costs (approximately $1.3 billion for the STEP trial program), manufacturing complexity (peptide synthesis and cold-chain distribution), and market positioning as a specialty medication. The company also prices to maximize revenue before patent expiration in 2031-2033.

Can I use GoodRx for Wegovy? Yes, but the discount is modest (typically $100-$200 off the cash price). You cannot combine GoodRx with insurance or the Novo Nordisk savings card. GoodRx is most useful for patients paying cash without insurance.

Does Costco have the cheapest Wegovy price? Yes. Costco's cash price is typically $100-$150 lower than CVS, Walgreens, or Walmart. You need a Costco membership ($60/year), but the savings on a single Wegovy fill justify the membership cost.

What if my insurance denies Wegovy? If PA is denied, ask your provider to submit an appeal with additional documentation (weight-loss history, comorbidities, previous medication trials). If the appeal fails, options include paying cash, switching to compounded semaglutide, or enrolling in a clinical trial.

Is oral semaglutide as effective as Wegovy injections? No. Rybelsus (FDA-approved oral semaglutide) produces 3-5% weight loss in diabetes trials compared to Wegovy's 15-17%. Compounded oral semaglutide efficacy isn't established in published trials. Injections have higher bioavailability and better weight-loss outcomes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2019.
3. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
4. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Novo Nordisk A/S. Wegovy Prescribing Information. 2024.
7. Novo Nordisk A/S. Rybelsus Prescribing Information. 2024.
8. IQVIA Institute. The Use of GLP-1 Receptor Agonists in the United States: Trends and Access. 2025.
9. Alliance for Pharmacy Compounding. Compounded GLP-1 Market Analysis. 2025.
10. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drug List. 2026.
11. GoodRx Research. Prior Authorization Approval Rates for Weight-Loss Medications. 2024.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Novo Nordisk A/S. Q4 2025 Earnings Call Transcript. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx, Costco, CVS, Walgreens, Walmart, and Sam's Club are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.